Dr. Finn discusses the follow-up of LEAP-002 and its clinical implications despite not meeting the primary end points.
Liver
Advertisement
The addition of concurrent chemoradiation to chemotherapy can improve OS and resection rates in patients with LAGBC.
LEAP-002 long-term follow-up suggests there may be benefit associated with len/pembro for patients with aHCC.
Dina Ioffe, MD, Fox Chase Cancer Center, talks about the use of immunotherapy in the neoadjuvant or adjuvant setting.
Researchers evaluated the efficacy and safety of hepatic arterial infusion chemotherapy as a first-line treatment option.
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Maen Abdelrahim reflects on the multidisciplinary collaboration required to make transplant oncology a clinical reality.
GI Oncology Now spoke with experts about HCC, how its management is changing, and how advancements are reshaping the disease.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.